Role of pro-inflammatory cytokines in rheumatoid arthritis

Springer Seminars in Immunopathology - Tập 20 - Trang 133-147 - 1998
Fionula M. Brennan1, Ravinder N. Maini1, Marc Feldmann1
1Kennedy Institute of Rheumatology, Hammersmith, UK

Tóm tắt

Rheumatoid arthritis (RA) is well known to be a chronic autoimmune/inflammatory disease which leads to progressive joint damage and destruction. Less well known is the fact that in severe cases of RA, with extra-articular manifestations and multiple joint involvement, there is also a significant reduction in life expectancy [28]. Hence the need for new therapeutic agents. With the cloning of cDNAs encoding cytokines in the early to mid 1980s, it became possible to use new assays to evaluate cytokine expression in the local site of autoimmunity, the rheumatoid synovium. There were two goals. First would understanding cytokine expression help us understand the pathogenesis of RA? Secondly, would it be possible to learn enough about the cytokine network to establish possible therapeutic targets? While a complete understanding of either of these questions remains elusive, here we review the state of knowledge in early 1998, which shows that much progress has been made and that these goals have been partly reached. The clinical benefits of this knowledge are documented elsewhere in this compilation, as is the role of chemokines, anti-inflammatory cytokines and the cytokines involved in neovascularisation.

Tài liệu tham khảo

Akahoshi T, Wada C, Endo H, Hirota K, Hosaka S, Takagishi K, Konso H, Kashiwazaki S, Matsushima K (1993) Expression of monocyte chemotactic and activating factor in rheumatoid arthritis. Arthritis Rheum 36: 762

Alvaro-Garcia JM, Zvaifler NJ, Firestein GS (1989) Cytokines in chronic inflammatory arthritis. IV. GM-CSF mediated induction of class II MHC antigen on human monocytes: a possible role in RA. J Exp Med 146: 865

Brennan FM, Chantry D, Jackson A, Maim R, Feldmann M (1989) Inhibitory effect of TNF a antibodies on synovial cell interleukin-I production in rheumatoid arthritis. Lancet II: 244

Bresnihan B, Lookbaugh J, Witt K, Musikic P (1996) Treatment with rIL-Ira in RA: results of a randomised double-blind, placebo-controlled multicentre trial. Arthritis Rheum 39: 5282

Buchan G, Barrett K, Turner M, Chantry D, Maim RN, Feldmann M (1988) Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-la. Clin Exp Immunol 73: 449

Butler DM, Maim RN, Feldmann M, Brennan FM (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNF-a antibody with the IL-1 receptor antagonist. Eur Cytokine Netw 6: 225

Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, Woody JN, Feldmann M, Maim RN (1998) Regulation of cytokines and acute phase proteins following TNF-α blockade in rheumatoid arthritis (submitted)

Cohen SBA, Katsikis PD, Chu CQ, Thomssen H, Webb LMC, Maim RN, Londei M, Feldmann M (1995) High IL-10 production by the activated T cell population within the rheumatoid synovial membrane. Arthritis Rheum 38: 946

Deleuran BW, Chu CQ, Field M, Brennan FM, Katsikis P, Feldmann M, Maim RN (1992) Localization of interleukin-la, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 31: 801

Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW (1988) Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet II: 706

Elliott MJ, Maim RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody J (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-α. Arthritis Rheum 36: 1681

Fouilhoux M, Chabaud M, Fossiez F, Miossec P (1997) Production of IL-17 and its regulation in rheumatoid synovium. Arthritis Rheum 40: S1447

Helle M, Boeije L, Groot E de, Vos A de, Aarden L (1991) Detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods 138: 47

Kirkham B, Portek I, Lenarcyzk A, Stavros B, Edmonds J (1997) Interleukin 17 mRNA expression in rheumatoid and psoriatic arthritis synovial membrane. Arthritis Rheum 40: S 1006

Maini RN, Paulus H, Breedveld FC, Moreland LW, William E, Russell AS, Charles P, Davies D, Grint P, Wherry JC, Feldmann M (1997) rHUIL-10 in subjects with active rheumatoid arthritis (RA): a phase I and cytokine response study. Arthritis Rheum 40 (Suppl): 5224

Maini RN, Breedveld FC, Kalden JR, Smolen IS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M (1998) Randomized placebo-controlled trial of multiple intravenous infusions of anti-TNF-a monoclonal antibody with or without weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1152

McInnes IB, al-Mughales J, Field M, Levnq BP, Hveng FP, Dixon R, Sturrock RD, Wilkinson PC, Lieu KY (1996) The role of interleukin 15 in T-cell migration and activation in RA. Nat Med 2:175

Sebbag M, Parry SL, Brennan FM, Feldmann M (1997) Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of TNF-α but not IL-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur J Immunol 27: 624

Williams RO, Mason LJ, Feldmann M, Maim RN (1994) Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 91: 2762

Williams RO, Mauri C, Mason L, Marinova-Mutafchieva L, Ross S, Feldmann M, Maim R (1998) Mechanisms of action of cyclosporin and anti-TNF-a in collagen-induced arthritis and effect of combination therapy. Arthritis Rheum (in press)